Tech Company Financing Transactions
NeurAxon Funding Round
NeurAxon closed a $32 million Series B investment round on 8/20/2007. Investors included Delphi Ventures, OrbiMed and BDC Venture Capital.
Transaction Overview
Company Name
Announced On
8/20/2007
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series B
Investors
Delphi Ventures (Lead Investor) (Deepa Pakianathan)
OrbiMed (Lead Investor) (Samuel Wertheimer)
Proceeds Purpose
"We believe that this substantial round of funding from blue-chip life science venture capital investors is areflection of the strong potential of our proprietary nNOS therapeutic platform. NeurAxon has generated aportfolio of next generation pain therapeutics targeting nNOS, and the Series B proceeds will be used to acceleratethe clinical development of our product candidates," commented Lawrence E. Bloch, M.D., J.D., Chief ExecutiveOfficer and Director of NeurAxon.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
16-1375 Southdown Rd. 318
Mississauga ON, L5J 2Z1
Canada
Mississauga ON, L5J 2Z1
Canada
Phone
Website
Email Address
Overview
NeurAxon is a leader in discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
John Andrews
VP - Regulatory Affairs
Tom Lategan
Browse more venture capital transactions:
Prev: 8/20/2007: Persu Vehicles venture capital transaction
Next: 8/20/2007: Jive Software venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs